PUBLISHER: The Business Research Company | PRODUCT CODE: 1948399
PUBLISHER: The Business Research Company | PRODUCT CODE: 1948399
A uterine fibroid embolization device is a medical device used in the treatment of noncancerous tumors, specifically uterine fibroids, through a minimally invasive procedure. Uterine fibroids are benign growths in the uterus, and this device functions by restricting the blood supply to these fibroids, causing them to shrink and ultimately disappear.
The main types of technologies associated with uterine fibroid embolization devices include surgical techniques, laparoscopic techniques, ablation techniques, and embolization techniques. Surgical techniques involve specific methods and procedures employed by medical professionals. These devices are utilized in various treatment modes, including invasive, minimally invasive, and non-invasive treatments. Additionally, they find application in diverse healthcare settings such as hospitals, clinics, and ambulatory surgical centers.
Tariffs are impacting the uterine fibroid embolization device market by increasing the import and manufacturing costs of embolic agents, microcatheters, delivery systems, and imaging-guided interventional components, leading to higher procedure costs across hospitals, clinics, and ambulatory surgical centers. The effect is more pronounced in regions relying on cross-border sourcing of interventional radiology devices, particularly in North America, Europe, and Asia-Pacific specialty care markets. Segments such as embolization techniques and minimally invasive treatment systems experience the strongest pricing pressure; however, tariffs are also encouraging domestic assembly, regional supply localization, and innovation in cost-efficient device design, which supports long-term supply resilience and market competitiveness.
The uterine fibroid embolization device market research report is one of a series of new reports from The Business Research Company that provides uterine fibroid embolization device market statistics, including uterine fibroid embolization device industry global market size, regional shares, competitors with a uterine fibroid embolization device market share, detailed uterine fibroid embolization device market segments, market trends and opportunities, and any further data you may need to thrive in the uterine fibroid embolization device industry. This uterine fibroid embolization device market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The uterine fibroid embolization device market size has grown steadily in recent years. It will grow from $5.93 billion in 2025 to $6.19 billion in 2026 at a compound annual growth rate (CAGR) of 4.4%. The growth in the historic period can be attributed to rising prevalence of uterine fibroids among women of reproductive age, growing number of hospital and clinic-based gynecological procedures, increasing adoption of uterine artery embolization in interventional radiology, greater awareness of alternatives to open surgical myomectomy, expansion of minimally invasive treatment workflows in tertiary care centers.
The uterine fibroid embolization device market size is expected to see steady growth in the next few years. It will grow to $7.33 billion in 2030 at a compound annual growth rate (CAGR) of 4.3%. The growth in the forecast period can be attributed to rising demand for uterus-sparing fibroid treatments in younger patient populations, growing clinical shift toward minimally invasive and non-invasive treatment modes, increasing procedural penetration in ambulatory surgical centers, expanding use of ablation and embolization devices for fibroid size reduction, rising investments in advanced delivery catheters and embolic systems to improve treatment precision. Major trends in the forecast period include rising adoption of minimally invasive embolization techniques for uterine fibroid treatment, increasing clinical preference for organ-preserving alternatives to hysterectomy, growing utilization of image-guided interventional devices for targeted fibroid therapy, expanding use of embolization procedures in outpatient and ambulatory surgical settings, increasing demand for precision delivery systems to improve procedural safety and outcomes.
The growing demand for minimally invasive surgeries is expected to drive the growth of the uterine fibroid embolization device market. Minimally invasive surgeries involve small incisions or the use of natural body openings to access and treat internal organs, tissues, or structures while minimizing trauma to the patient. The demand for these procedures is increasing as patients and healthcare providers seek treatments that reduce recovery time, lower complication risks, and improve overall comfort. Uterine fibroid embolization devices facilitate these procedures by enabling precise and effective treatment of fibroids, improving patient outcomes and procedural efficiency. For instance, in January 2025, according to AOS Open, a US-based medical journal, hospitals with robotic-assisted systems reported that minimally invasive surgeries accounted for 65.8% of procedures in 2025, up from 60.5% in 2022. Therefore, the growing demand for minimally invasive surgeries is propelling the uterine fibroid embolization device market.
Companies in this market are focusing on innovations such as minimally invasive fibroid management software to improve precision and efficiency in uterine fibroid treatment. This type of software provides clinicians with advanced digital tools to plan, guide, and execute minimally invasive procedures, enhancing procedural accuracy, safety, and patient outcomes. For example, in September 2024, Gynesonics, a US-based medical device company specializing in minimally invasive gynecologic treatments, launched SMART OS 2.4 software for the Sonata System. The software reduces the minimum ablation zone size from 2.0 X 1.3 cm to 1.6 X 1.2 cm, decreases ablation volume by 38%, and optimizes the Thermal Safety Border for smaller fibroids, enabling more controlled treatments while preserving healthy uterine tissue.
In October 2024, Hologic Inc., a US-based medical technology company, acquired Gynesonics for $350 million. This acquisition expands Hologic's portfolio of minimally invasive treatment options for women's health, particularly in the management of uterine fibroids and heavy menstrual bleeding. Gynesonics develops minimally invasive solutions for the treatment of symptomatic uterine fibroids, and its integration strengthens Hologic's position in the women's health market.
Major companies operating in the uterine fibroid embolization device market are Johnson and Johnson Pvt Ltd., Medtronic plc., Boston Scientific Corporation, Olympus Corporation, Terumo Corporation, Ethicon Inc., Hologic Inc., CooperSurgical Inc., Cook Medical Inc., Karl Storz GmbH, Merit Medical Systems, CONMED Corporation, Lumenis Ltd., Richard Wolf GmbH, BTG International Ltd., Healthium MedTech Pvt. Ltd., Hironic Co.Ltd, Minerva Surgical Inc., Gynesonics Inc., Advanced Surgical Concepts PLLC
North America was the largest region in the uterine fibroid embolization device market in 2025. The regions covered in the uterine fibroid embolization device market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the uterine fibroid embolization device market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The uterine fibroid embolization device market consists of revenues earned by entities by provide services such as minimally invasive procedures, non-invasive procedures, minimally invasive procedures, radiofrequency ablation, medication and hormonal therapy, and embolization procedures. The market value includes the value of related goods sold by the service provider or included within the service offering. The uterine fibroid embolization device market also includes sales of medications, hysteroscopic devices, laparoscopic devices, radiofrequency ablation devices, endometrial ablation devices, hysterectomy devices, and robotic surgical systems. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Uterine Fibroid Embolization Device Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses uterine fibroid embolization device market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for uterine fibroid embolization device ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The uterine fibroid embolization device market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.